Let's just talk about ATL1102 for Stem Cells Mobilisation for now.
If it is an approved compound, its sales is $200m per annum until 2031 (US patent pending) or roughly $3 billion worth of sales starting from 2016.
So from Phase 1 to marketing approval, we have a gap of 2cps (MC $20m) and $3 (MC $3b) per share to be filled in the next 3 years.
If we use an oil exploration company like WHN to illustrate the point. WHN has an MC of $50m (went as high as 70m in Nov 2011)for a completed 2D seismic work. (equivalent to an IND (investigative new drug) approval status in Biotech term) Yet ANP is lingering around MC of $20m.
So, the current SP of ANP is probably a reflection of ASX being a Mining and Oil centric market.
May be this article on Four Events that can Trigger a Biotech Stock Re-rating may show that ANP has ticked all the boxes on the re-rating events suggested,
regardless of how the local market is treating it at the moment.
JIMO
cheers
- Forums
- ASX - By Stock
- PER
- atl1102 a clear winner
atl1102 a clear winner, page-30
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
0.004(5.26%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
7.9¢ | 8.0¢ | 7.7¢ | $35.48K | 451.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 12500 | 7.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 198147 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1471 | 0.077 |
1 | 69866 | 0.074 |
1 | 75000 | 0.073 |
2 | 15000 | 0.070 |
1 | 100000 | 0.067 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 198147 | 2 |
0.081 | 198015 | 2 |
0.082 | 75174 | 2 |
0.083 | 93000 | 1 |
0.084 | 200300 | 2 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |